Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) shares rose 5.1% during trading on Monday . The company traded as high as $22.19 and last traded at $22.21. Approximately 659,940 shares changed hands during mid-day trading, an increase of 22% from the average daily volume of 542,139 shares. The stock had previously closed at $21.13.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on IART shares. Citigroup boosted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Morgan Stanley began coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price on the stock. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $23.00.
Read Our Latest Analysis on IART
Integra LifeSciences Stock Performance
The company has a market cap of $1.79 billion, a P/E ratio of -258.53, a P/E/G ratio of 0.73 and a beta of 1.17. The firm has a 50 day moving average price of $23.74 and a 200-day moving average price of $21.84. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.89 EPS. On average, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.
Insider Transactions at Integra LifeSciences
In other news, EVP Michael J. Mcbreen sold 1,700 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.10% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Integra LifeSciences
Several large investors have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY lifted its position in shares of Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after purchasing an additional 901,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Integra LifeSciences by 16.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 198,642 shares of the life sciences company's stock worth $4,505,000 after purchasing an additional 28,457 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Integra LifeSciences during the 4th quarter worth about $2,512,000. Soleus Capital Management L.P. acquired a new position in Integra LifeSciences in the 4th quarter valued at approximately $28,940,000. Finally, Two Sigma Advisers LP raised its holdings in Integra LifeSciences by 4.5% in the 4th quarter. Two Sigma Advisers LP now owns 536,000 shares of the life sciences company's stock valued at $12,156,000 after acquiring an additional 23,300 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.
About Integra LifeSciences
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
